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Abstract 
Inflammation is a well-accepted cause of insulin resistance (IR), and anti-inflammatory 
treatments (AITs) are supposed to improve insulin sensitivity. Herein, we revealed that 
knockout of a potent anti-inflammatory protein: murine regenerating islet-derived protein 
3β (REG3β), paradoxically enhanced insulin sensitivity, and completely blocked 
development of IR induced by lipopolysaccharide (LPS) or dextran sulfate sodium 
(DSS)-mediated inflammation in mice. These knockout effects were reversed by 
exogenous REG3β administration, and conferred by ablating two previously-unknown 
bindings of REG3β to transmembrane proteins exostosin-like glycosyltransferase 3 
(EXTL3) that suppressed expression of insulin receptor (INSR) and protein kinase B 
(AKT) and cytokine receptor C-X-C motif chemokine receptor 4 (CXCR4) that inhibited 
phosphorylation of INSR and AKT. Prior conflicting effects of anti-inflammatory drugs 
on insulin sensitivity could now be explained by their different ability to alter tissue 
REG3β protein. Suggested human homologue regenerating islet-derived protein 3α 
(hREG3α) exhibited similar functions to those of REG3β. Our work unveiled REG3β as a 
potent negative determinant of insulin sensitivity and an essential mediator for 
inflammation to induce IR. These findings drastically revise current theory on the 
relationship of inflammation and IR, and offer an exciting new therapy target of IR and a 
safer, alternative prospect to treat inflammation in diabetes. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Current research on inflammation and insulin. 
Systemic inflammation is a well-recognized contributor to the development of IR (Feve 
and Bastard, 2009; Finucane et al., 2015; Ghorpade et al., 2018; Pickup et al., 1997; Tian 
et al., 2016), whereas AITs are supposed to prevent or ameliorate the development 
(Ghorpade et al., 2018). Experiments confirmed the role of cytokine, tumor necrosis 
factor alpha (TNFα), and its receptor-associated factor (TRAF1) in the development of 
insulin resistance (Hotamisligil et al., 1993; Xiang et al., 2016). Same as TNFα, 
interleukin 1 beta (IL-1β) was demonstrated to inhibit insulin sensitivity (Finucane et al., 
2015; Jager et al., 2007). Moreover, a recent study demonstrated interleukin 1 (IL-6) 
produced by macrophages stimulated adipose tissue inflammation leading to hepatic 
insulin resistance (Perry et al., 2015). Similarly, natural killer cells and conventional 
dendritic cells were proved a crucial link between visceral adipose tissue inflammation 
and insulin resistance (Macdougall et al., 2018; Wensveen et al., 2015).  Additionally, 
research revealed that dipeptidyl peptidase-4 (DPP4) secreted from hepatocytes promoted 
adipose inflammation and further promoted insulin resistance. This finding emphasized 
the crosstalk between inflammation and hepatic insulin resistance (Ghorpade et al., 
2018). However, inactivating or suppressing key cytokine and interleukin genes in the 
currently-recognized inflammation-induced IR pathway failed to improve or even 
impaired insulin sensitivity. Likely, even though overexpression of TNFα contributes to 
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the development of insulin resistance, knockout of TNFα failed to protect mice from 
insulin resistance efficiently (Ventre et al., 1997; Wascher et al., 2011). And, a recent 
paper even showed that down-regulated TNFα worsened glucose homeostasis (Wu et al., 
2018) and from two other papers, IL-1 receptor antagonist (IL-1Ra) application showed 
two reversed effects on IR (Larsen et al., 2007; van Asseldonk et al., 2015). Meanwhile, 
anti-inflammatory drugs exert conflicting effects on alleviating the inflammation-induced 
IR. Sodium salicylate was discovered to improve insulin sensitivity (Ebstein, 2002) and a 
2-week high-dose aspirin treatment was found to be able to bring fasting plasma glucose
back to normal (Ford et al., 2015; Reid et al., 1957), though strong side effects limited its 
application in insulin resistant patients (Garcia Rodriguez et al., 2016). Statins as an anti-
inflammatory drug was reported to have little effect on improving (Chan et al., 2002) or 
even impairing insulin sensitivity in a subsequent clinical study(da Silva et al., 2018; 
Preiss et al., 2011). Moreover, applying dexamethasone, another anti-inflammatory drug, 
decreased 30-40% insulin sensitivity (Buren et al., 2002; Pereira et al., 2014; Perry et al., 
2003). Some drugs like Tocilizumab showed varied responses (Chen et al., 2015; 
Makrilakis et al., 2015; Tournadre et al., 2017). Apparently, the relationship between 
inflammation and IR and the underlying mechanism are far more complicated than our 
current understanding. 
1.2 REG3β. 
Murine REG3β (REG3β) is one of the 12 identified islet-derived regenerating protein 
family (REG) members (Iovanna and Dagorn, 2005; Liu et al., 2008). This 17-kDa, 
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secreted protein (Iovanna and Dagorn, 2005) is highly expressed in pancreas and intestine 
(Gironella et al., 2013; Gironella et al., 2005). The Clustal Alignment analysis 
(Thompson et al., 2002) suggests human regenerating islet-derived protein 3α (hREG3α) 
and murine REG3β (mREG3β) are homologues and research also demonstrated that 
hREG3α has similar function with REG3β (Lai et al., 2012; Mukherjee et al., 2014; 
Orelle et al., 1992; Pickert et al., 2009). REG3β is known as a regenerating protein since 
it was reported to be detected in the serum or the pancreatic juice of pancreatic ductal 
adenocarcinomas patients (Xie et al., 2003) and promoted pancreatic cancer growth 
(Folch-Puy, 2013; Gironella et al., 2013; Liu et al., 2015) and tissue regeneration in rats 
with acute pancreatitis (Keim et al., 1991), pancreatectomy mice (Rankin and Kushner, 
2010), injured intestine regeneration (Lindemans et al., 2015) and the brain tissue of 
Alzheimer patients (Duplan et al., 2001). Absence of REG3β significantly impaired 
heart-healing processes (Lorchner et al., 2015). REG3β was also reported to play a role in 
antimicrobial functions (Miki et al., 2012) by inhibiting intestinal bacterial translocation 
upon oral infection with Gram-negative Salmonella (van Ampting et al., 2012). 
Moreover, REG3β is known as an important protein involved in the anti-inflammation of 
the pancreas and intestine by suppressing NF-kappa B activation (Aden et al., 2016; 
Folch-Puy et al., 2006; Gironella et al., 2007; Ogawa et al., 2003). However, its 
involvement in the inflammation-induced IR could never have been imaged until we 
serendipitously found exceptionally high insulin sensitivity in the REG3β-/- mice used for 
an early study (in 2013) of hepatotoxicity (Yun et al., 2013). After knowing its dual role 
in anti-inflammation while impairing insulin sensitivity, we hypothesized that REG3β 
might serve as an intriguing mediator to connect inflammation to the induced IR, 
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responsible for the paradoxical effects of cytokines, interleukins, and anti-inflammatory 
drugs on insulin sensitivity. 
To understand how REG3β mediate insulin sensitivity, we explored the mechanism on 
transcription and phosphorylation. To explore the possible mechanism of REG3β on the 
transcription of insulin signal pathway genes, we performed a database search by TESS 
(http://www.cbil.upenn.edu/tess/) to identify transcription factors target to the 
proximal promoters of these genes. Among the transcription factors we found during our 
searching process, glucocorticoid receptor (NR3C1) become our primary target for three 
reasons: 1) previous research showed that NR3C1 was associated with glucose stimulated 
insulin secretion (GSIS) (van Raalte et al., 2012) and insulin level (van Rossum et al., 
2002). Moreover, the inhibition of glucocorticoids on insulin sensitization is documented 
(Geer et al., 2014). Additionally, ChIP assay identified several target genes of NR3C1 
including insulin signaling transactivation genes (Wang et al., 2004) [insulin receptor 
substrate 1 (Irs1)]. These findings demonstrated the involvement of NR3C1 on insulin 
sensitivity; 2) REG3β was reported to stimulate M2 macrophage polarization with high 
expression of NR3C1 indicate that REG3β might regulate NR3C1 expression (Wynn and 
Vannella, 2016); 3) we identified several binding sites of NR3C1 on the proximal 
promoter region of Insr/Akt1/Akt2.  
Moreover, to link the endocrine-like, extracellular REG3β to the possible action of 
NR3C1 in the transcriptional inhibition of insulin signal pathway genes needs a 
transmembrane protein as a binding partner of REG3β. We conducted an exhaustive 
literature search and found EXTL3 (a membrane protein and a glycosyltransferase that 
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regulates the biosynthesis of heparan sulfate) (Busse et al., 2007) as the most promising 
candidate. This was because: 1) EXTL3 is be able to bind the human homologue of 
REG3β: hREG3α and regenerating islets derived protein 1 alpha (REG1α) that all 
contain C-type lectin domain, which is reported to bind with EXTL3 (Van Ba et al., 
2012; Wu et al., 2016b); and 2) heparan sulfate proteins, produced by the catalysis of 
EXTL3 (Busse et al., 2007), could activate NR3C1 via stepwise interactions with 
fibroblast growth-factor and fibroblast growth-factor receptor complex to activate 
mitogen-activated protein kinase (ERK1/2) (Galanternik et al., 2015), the complex of tau 
1 transactivation domain of NR3C1(Dahlmanwright et al., 1994) with cAMP response 
element binding protein (Almlof et al., 1998). Thus, REG3β has a good potential to bind 
to EXTL3 and further activate NR3C1 to inhibit the transcription of insulin signal 
pathway genes.  
To explain the possible intriguing mediator role of REG3β to connect inflammation to the 
induced IR, we need to explore the possible mechanism of REG3β on the 
phosphorylation inhibition of insulin signal pathway proteins under inflammation. We 
conducted an exhaustive literature search and identified suppressor of cytokine signaling 
3 (SOCS3) (an anti-inflammatory protein) as the primary candidate for the following 
reason: 1) both REG3β and SOCS3 can be stimulated by either inflammatory or anti-
inflammatory cytokines like TNFα and IL-6 (Zhang et al., 2006; Zhang et al., 2014). 
Also REG3β was reported to activate signal transducer and activator of transcription 3 
(STAT3) (Lorchner et al., 2015), which is a stimulator of SOCS3 (Ramadoss et al., 
2009). This made REG3β a very promising regulator of SOCS3 as well; 2) SOCS3 was 
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proved as an important insulin sensitivity suppressor under inflammation condition by 
inhibiting the phosphorylation of INSR and AKT (Carow and Rottenberg, 2014); 3) to 
our best knowledge, other inflammation induced insulin sensitivity suppressors like p38 
mitogen-activated protein kinases (P38) was not reportedly correlated with REG3β.  
Also, to link extracellular REG3β to the possible action of SOCS3 in the phosphorylation 
inhibition of insulin signal proteins needs a transmembrane protein as a binding partner 
of REG3β. However, after an exhaustive literature search, EXTL3 was not found to have 
any association with the phosphorylation of insulin signal proteins. But, we identified 
CXCR4 and glycoprotein 130 (GP130) (well-known transmembrane inflammatory 
cytokine receptors (Wescott et al., 2016) that could be stimulated by inflammation) as our 
primary candidates for exerting the function of REG3β on phosphorylation inhibition of 
insulin signal proteins for the following reasons: 1) SOCS3 was shown to be directly 
stimulated by CXCR4 and GP130 (Takekoshi et al., 2013) in the presence of its ligand C-
X-C motif chemokine ligand 12 (CXCL12) or IL-6; 2) the CXCL12/CXCR4 complex or 
IL-6/GP130 complex was speculated to be the target of REG3β in cancer cells (Loncle et 
al., 2015); and 3) other important cytokine receptors were not reported as targets of  
REG3β. Thus, we hypothesized that REG3β is likely binding to CXCR4/GP130 and 
further activates SOCS3 to inhibit phosphorylation of the insulin signal pathway proteins. 
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CHAPTER TWO 
OBJECTIVES AND EXPERIMENTAL PROTOCOLS 
2.1 Aims 
Regenerating islet-derived protein 3β (REG3β) has been identified as an anti-
inflammatory protein essential in tissue regeneration and cancerogenesis. Since the 
reason for inconsistent effects of anti-inflammatory drugs on treating insulin resistance is 
still unknown, our study was designed to test 1) if REG3β acted as a negative determinant 
of the baseline insulin sensitivity; 2) if REG3β was the key mediator for the systemic 
inflammation induced IR and 3) what the subsequent mechanism of REG3β on insulin 
signaling was.  
2.2 Experimental Procedures 
2.2.1 Animals, treatments, and metabolic response detection. 
The genetic background of REG3β knockout (KO) and wildtype (WT) mice 
(129/S6×C57BL/6), feeding and housing conditions, and tissue sampling were the same 
as previously described (Wang et al., 2008). All mice used in this research were male and 
2-months old unless otherwise indicated. In determining effects of REG3β on insulin 
sensitivity, insulin tolerance test (ITT), glucose tolerance test (GTT), glucose stimulated 
insulin secretion (GSIS), plasma insulin assay (ELISA kit, Crystal Chem, Downers 
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Grove, IL) and plasma C-reactive protein (CRP) assay (ELISA kit, Cayman chemical, 
Ann Arbor, MI) were performed in fasting (overnight for 8 h) WT and KO mice (n = 6) 
as previously-described (Wang et al., 2008). In determining acute effects of recombinant 
REG3β protein administration on insulin sensitivity, a single ip injection of filter-
sterilized REG3β protein at 2 µg/g body weight or equal volume [10 µl/g body weight 
(BW)] of PBS was given to the WT and KO male mice (n = 6) at 15 min prior to the 
administration of insulin (0.5 U of insulin/kg BW) and mice were euthanized within 5 
min after the injection of insulin to collect tissues for immunoblotting analysis. In 
determining long-term effects of REG3β administration, daily ip injections of REG3β at 
2 µg/g or PBS (control) were given to KO mice (n = 6) for 6 wk followed by ITT. In 
determining acute effects of inflammation on REG3β protein expression in the pancreas 
and intestine, and the subsequent impact on insulin sensitivity, WT and KO mice were 
given an ip injection of PBS or LPS (2 mg/kg BW) followed by ITT test at 12 hours after 
injections. Tissues and plasma were collected after ITT for qPCR, CRP, and 
immunoblotting analyses. In determining long-term effects of inflammation on REG3β 
protein expression in pancreas and intestine and the subsequent impact on insulin 
sensitivity, 2% DSS was added to drinking water for 2 wk followed by ITT at the end of 
the experiment. Tissues were collected after ITT for immunoblotting analysis. In 
determining effects of eliminating circulating REG3β protein in plasma on insulin 
sensitivity, 0.4 µg/g BW REG3β antibody or pre-immune rabbit serum (average BW, 25 
g) were injected every other day for 2 wk followed by ITT at the end of the experiment.
In determining acute effects of anti-inflammation drugs on REG3β protein expression in 
the pancreas and intestine, WT and KO mice were given an ip injection of PBS or 
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dexamethasone (DEX) (0.12 µg/g BW) followed by ITT at 6 h after injections. WT and 
KO mice were given an ip injection of aspirin (81 mg/kg BW, 10% DMSO) or statin (40 
mg/kg BW, saline) 1 h prior to LPS injection (2 mg/kg BW) with drug solvent as control 
followed by ITT at 6 h after injections. Ibuprofen (25%) and sulindac (3%) were added to 
drinking water (to target a dose of 40 or 5 µg/g BW) for 4 wk to mice that were injected 2 
mg/kg BW LPS every other day. Tissues from these studies were collected for 
immunoblotting analysis. In determining acute effects of recombinant REG3α protein 
administration on insulin sensitivity, a single ip injection of filter-sterilized REG3α 
protein at 4 µg/g BW or equal volume (10 µl/g BW) of PBS was given to the WT and 
KO male mice (n = 6) at 15 min prior to ITT.  
2.2.2 Q-PCR, Immunobloting, immunohistochemistry and H&E staining, 
hepatocyte isolation, culture, and treatments.  
Q-PCR and immunoblotting were performed as previously described with primers and
antibodies listed in Appendix Table 1 and 2 (Yan et al., 2012). The whole pancreas and 
intestine tissue were removed from mice, fixed in 4% paraformaldehyde at 4°C 
overnight, washed 3 times in PBS, transferred into 70% ethanol, and placed into a 
cassette for embedding (Sund et al., 2001). The embedded samples were sectioned at 5 
µm, and the slides were rehydrated through xylenes and decreasing grades of alcohol and 
stained (H & E) at the Cornell histology facility (Ithaca, NY). Staining was viewed using 
an Axiovert 200 M fluorescent microscope (Zeiss, Carl-Zeiss-Strasse, Oberkochen, 
Germany). The primary hepatocytes were isolated from the WT and KO mice by type IV 
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collagenase (2 mg/mL, Sigma-Aldrich) digestion of liver following a standard protocol 
with minor modifications (Severgnini et al., 2012). The isolated hepatocytes were then 
cultured in William Medium E (WME) media for 12 h at 37°C (5% CO2) before being 
treated with 20 ng/mL REG3β protein for 6 h. Hepatocytes untreated with REG3β served 
as a negative control. Relative mRNA level of Insr, Akt1-3, C/ebpb, Nr3c1, Hnf3b, Wt1 
and C/ebpd was measured by Q-PCR.  
2.2.3 Heterologous expression and purification of native Reg3β and Reg3α proteins
The NOD mouse Reg3β cDNA (NM_011036), human Reg3α cDNA (NM_002580) 
human Cxcl12 (NM_000609) or human Il6 (NM_000600) were inserted into the Pichia 
pastoris expression vector pPICZ (Invitrogen, Grand Island, NY) in a way that allowed 
expression of REG3β, REG3α, CXCL12 and IL6 with His-tag at the C-terminus and 
without the respective intrinsic signal peptide sequences at the N-terminus using XhoI 
and EcoRI or SacI and XhoI restriction sites. This construct and vector pPICZαC were 
digested with BstBI and EcoRI, and then the Reg3β, Reg3α, Cxcl12 or Il6 - fragment was 
ligated into the pPICZ vector backbone to create Reg3β or Reg3α - pPICZαA.  
Chemically competent E. coli was transformed via heat shock (Froger and Hall, 2007). 
Sequence verification was performed by Big Dye Terminator chemistry at the Cornell 
Biotechnology Resource Center (Ithaca, NY). Isolated Reg3β or Reg3α plasmids were 
transformed into the yeast P. pastoris GS200 using electroporation (BTX, Holliston, MA) 
(Lin-Cereghino et al., 2005), and cultured in BMMY media for 3 d. Thereafter, the 
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culture supernatant was collected and brought to 40% saturation with ammonium sulfate 
to precipitate the REG3β or REG3α proteins (Yamada et al., 2012). The precipitates were 
dissolved in 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole at pH 8.0, and then 
dialyzed against the same buffer. Next, the dialyzed solutions were subjected to Ni-NTA 
column (Qiagen, Hilden, Germany) following manufacture instructions and the purity of 
the target proteins was verified by SDS-PAGE and immunoblotting. The REG3β or 
REG3α containing fractions were pooled, concentrated by 40% ammonium sulfate 
precipitation, and dissolved in and dialyzed against PBS at pH 7.4. 
2.2.4 Putative transcription factor binding sites and Chromatin 
immunoprecipitation (ChIP) assay 
The proximal promoter regions of Insr, Akt1, and Akt2 defined as -1,000/1,100 bp 
upstream of the transcription start site, were retrieved from the NIH/NCBI Entrez Gene 
database (http://www.ncbi.nlm.nih.gov/gene). The transcription factor binding sites were 
predicted using the Transcription Element Search System (TESS, http://www.cbil.upenn.	edu/cgi-bin/tess/tess).  
ChIP assay was performed using Imprint Chromatin Immunoprecipitation Kit (Sigma-
Aldrich, St. Louis, MO) according to the manufacturer’s instructions. Chromatin isolated 
from the WT and KO hepatocytes was immune-precipitated with antibodies against 
NR3C1 (Novus Biologicals, Littleton, CO) (Appendix Table 2) or mouse IgG (Sigma-
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Aldrich, St. Louis, MO). Three or four sets of primers covering the proximal regions of 
the Insr, Akt1 and Akt2 promoters were used for PCR analysis (Appendix Table 1).  
2.2.5 Luciferase reporter assays of the Insr and Akt1-2 gene promoter
Various promoter regions of Insr and Akt1-2 (-1100/-1000 to 0, -500 to 0, -250 to 0) were 
amplified using forward and reverse primers adding restriction sites (underlined) - Kpn I 
and Nhe I (New England Biolabs, Ipswich, MA) for cloning into corresponding sites of 
pGL3-basic luciferase reporter vector (Promega, Madison, WI) (Appendix Table 1). 
Constructed Insr and Akt1-2 promoter-luciferase reporter vectors were characterized by 
restriction analysis and DNA sequencing. The PCR protocol was 95ºC for 7 min followed 
by 35 cycles of 95ºC for 30 sec, 64ºC for 30 sec, and 72ºC for 1.5 min. The PCR products 
were purified using Wizard SV gel and PCR cleanup columns (Promega, Madison, WI), 
digested by aforementioned restriction enzymes, and ligated into the pGL3-basic 
luciferase reporter vector by T4 DNA ligase (Invitrogen, Grand Island, NY). The ligated 
vector was transformed into E. coli DH5α competent cells using heat shock (Froger and 
Hall, 2007).  
HepG2 cells were grown in WME media supplemented with 10% FBS, 10 mM HEPES, 
1 mM sodium pyruvate, 1% PenStrep, 0.4% fungizone, 5 µg/ml insulin, 1 µg/ml 
glucagon (Gibco, Grand Island, NY) and 0.5 µg/ml hydrocortisone (Sigma, St. Louis, 
MO) at 37ºC in 5% CO2 atmosphere. HepG2 cells were seeded in 6-well plates, grown to 
80–90% confluence, and transfected by LipofectamineTM 2000 (Invitrogen, Grand Island, 
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NY) according to the manufacturer’s instructions. Cells were transfected with the pGL3-
basic luciferase reporter vectors with the proximal promoters of Insr and Akt1-2 and 
Renilla luciferase control reporter vector (Promega, Madison, WI) for transfection 
efficiency normalization. After 24 h of transfection, cells were treated with 20 ng/ml 
REG3β for 12 h, and then were harvested in passive lysis buffer (Promega, Madison, 
WI). Luciferase activity was measured using the Dual-Luciferase Reporter Assay system 
(Promega, Madison, WI) on a Berthold Lumat LB 9501 (Berthold, Wildbad, Germany). 
2.2.6 Constructs of REG3β protein conjugated with enhanced green fluorescent 
protein (EGFP) (Reg3β-EGFP), CXCR4 protein conjugated with mCherry (Cxcr4-
mCherry), and EXTL3 protein conjugated with mCherry (Extl3-mCherry) 
For testing the binding between REG3β and CXCR4 or EXTL3, the NOD mouse Reg3β 
cDNA (NM_011036), mouse Cxcr4 (NM 001356509) and mouse Extl3 (NM 001360385) 
were inserted into the PcDNA 3.0-EGFP vector or pmCherry-C3 vector (Appendix Tables 
1 and 3) in a way that allowed expression of REG3β, CXCR4, and EXTL3 with EGFP or 
mCherry tag at the N or C-terminus using XhoI and HindIII, XhoI and SalI or HindIII 
and KpnI restriction sites. These constructs were used for co-immunoprecipitation (Co-
IP) and fluorescent co-localization assay.  
2.2.7 Co-immunoprecipitation 
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After REG3β-EGFP was overexpressed extracellularly in the HepG2 cells for 48 h and 
bound with intrinsic CXCR4 in the presence of CXCL12-His (produced in yeast) or 
intrinsic GP130 in the presence of IL6-His (produced in yeast) added into the medium, 
the binding complex was cross-linked by 1 mM disuccinimidyl suberate (DSS) (Thermo 
Scientific, Waltham, MA) for 30 min according to the manufacturer’s instructions.  
Thereafter, the binding complex was pulled-down by the GFP-trap beads (chromotek, 
Planegg, Germany) or mouse IgG and protein G beads (Santa Cruz, Dallas, TX) (Zhong 
et al., 2007) in dilution buffer containing 150 mM NaCl, 0.5 mM EDTA and 10 mM Tris-
HCl (pH=7.5), at 4°C overnight. Samples were washed 3 times with ice-cold dilution 
buffer, and proteins were eluted using an SDS-PAGE loading buffer at 100°C for 5 min 
(Cheng et al., 2003). After centrifugation, supernatant was loaded into SDS-PAGE gels 
for immunoblotting detection with CXCR4 or GP130/His-tag/REG3β antibodies 
(Appendix Table 2). 
After EXTL3-mCherry was overexpressed in the HepG2 cells for 48 h and bound with 
REG3β protein (produced in yeast) added into the medium, the binding complex was 
pulled down by an EXTL3 antibody or mouse IgG with protein G beads (Santa Cruz, 
Dallas, TX) in buffer containing 20 mM Tris HCl (pH = 8), 137 mM NaCl, 1% nonidet 
P-40 (NP-40), 2 mM EDTA (pH=7.5) at 4°C overnight. Samples were washed 5 times
with ice-cold buffer, and proteins were eluted using an SDS-PAGE loading buffer at 
100°C for 5 min (Germino et al., 1993). After centrifugation, supernatant was loaded into 
SDS-PAGE gels for immunoblotting detection with REG3β antibody (Appendix Table 2). 
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2.2.8 Co-localization of REG3β-EGFP with CXCR4-mCherry or EXTL3-mCherry 
HEK293T cells (1×105 cells/mL) were seeded the day before transfection. The Reg3β-
EGFP or GFP vectors were then transfected into the HEK293T cells by using PEI 
(Boussif et al., 1995). The cells were incubated in DMEM media with 10% FBS, 1% 
PenStrep at 37°C with 5% CO2. After 3 to 4 d, conditioned media (CM) was collected for 
the co-localization assay. REG3β-EGFP protein expression was measured by using an 
Axiovert 200 M fluorescent microscope (Zeiss, Carl-Zeiss-Strasse, Oberkochen, 
Germany). Human HepG2 cells were transfected with plasmid DNA of Extl3-mCherry or 
Cxcr4-mCherry by using lipofectamineTM2000 (Invitrogen) according to the 
manufacturer’s instructions. After 48 h of incubation, the cells were washed with HBH 
containing 137 mM NaCl, 5.4 mM KCl, 0.4 mM MgSO4*7H2O, 0.4 mM KH2PO4, 1.3 
mM CaCl2*2H2O, 0.3 mM Na2HPO4*7H2O, 20 mM HEPES (pH 7.4), and 0.1% BSA 
twice and then incubated with CM for 2 h at room temperature (Truong and Ikura, 2001). 
Cells were further washed with ice cold HBH for 3 times and then images of 
fluorescences were captured by using a Zeiss 880 Confocal-MP Inverted microscope 
(Zeiss, Carl-Zeiss-Strasse, Oberkochen, Germany). 
2.2.9 siRNA knockout and 1,9-Dimethylmethylene Blue (DMB) assay   
After 12 h seeding of HepG2 cells in 6-well plates at density (7.5 × 105 cells/mL), siRNA 
(Santa Cruz, Dallas, TX) against Extl3 or Nr3c1 and control siRNA were transfected to 
cells with lipofectamineTM 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Transfection reagent was removed after 12 h incubation with 
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complete WME medium. After 36 h of incubation, cells were either collected for qPCR 
analysis or treated with 20 ng/mL REG3β for 6 h before being processed for qPCR 
analysis or dimethylmethylene blue (DMB) binding assay.  
DMB binding assays were performed to quantify the levels of total glycosaminoglycans 
(GAG) chains on the HepG2 cell surface. Approximately 1 × 105 cells from each 
treatment were collected in 200ul PBS. Then, DMB (250 µL/well, Sigma-Aldrich, St. 
Louis, MO) was added to 25 µL of sample and quantified at 520 nm. 
2.2.10 Statistical analysis
Quantitative data of genotypic differences and various treatment effects were analyzed 
using one-way ANOVA with or without time-repeated measurements (SAS 6.11 
software, SAS Institute, Cary, NC). Values were expressed as mean ± SEM. Significance 
was defined as P < 0.05 unless indicated otherwise. 
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CHAPTER THREE 
RESULTS 
3.1 Knockout of REG3β enhanced insulin sensitivity and inhibited the inflammation 
induced insulin resistance  
The exceptional baseline insulin sensitivity in the REG3β-/- mice was initially shown by 
their “glucose shock” after an injection (ip) of a regular dose of insulin [0.5 units (U)/kg]. 
A half dose (0.25 U/kg) led to 2.3-7 fold greater decreases (P < 0.05) of blood glucose at 
30 and 60 min in the REG3β-/- than wild-type mice (WT) at both young (2-month) and 
old (10-month) ages (Fig. 3.1 and 3.2). Consistently, the REG3β-/- mice had 17.5-30.8% 
lower (P < 0.05) plasma glucose concentrations (Fig. 3.3) and 59% lower (P < 0.05) 
glucose-stimulated insulin secretion (Fig. 3.4) than the WT, despite similar body weights 
(Fig. 3.5). More convincingly, to determine the physiological relevance between 
improved insulin sensitivity and REG3β deletion, we administered KO mice multiple bi-
daily injections of the purified REG3β protein overexpressed and purified from the yeast 
and the knockout resultant enhancement of insulin sensitivity was reversed by exogenous 
REG3β administrations (2 µg/g of body weight, ip injection) for 6wk (Fig. 3.6 and 3.7). 
Therefore, REG3β acted as a specific, potent, and negative determinant of the baseline 
insulin sensitivity. Most strikingly, treating both genotypes with 2mg/kg BW LPS by i.p. 
injection 12 h prior to performing an insulin tolerance test (ITT, 0.25U/kg BW) or 2% 
DSS in the drinking water for 2 wk induced IR (29%) only in the WT (Fig. 3.8 and 3.9).  
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The LPS or DSS induced IR concurred with a substantial elevation of REG3β (P< 0.05) 
in the pancreas and intestine (Fig. 3.10 and 3.11). Although inflammation was produced 
by LPS and DSS in both genotypes, as confirmed by tissue pathology shown as more 
gaps in the pancreas and looser connections between cells and watery fecal in the 
intestines (H&E staining and dissection observation) and plasma C-reactive protein 
(CRP) elevation (Fig. 3.12-3.14), knockout of REG3β precluded the resultant 
inflammation from inducing IR in the mice.   
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Figure 3.1 Enhanced insulin sensitivity, as shown by the insulin tolerance test (ITT, 0.5 U/kg) in the KO compared with the WT mice 
after 8 h overnight fasting at 2- and 10-month ages. Data are mean ± SE (n = 6-10) *, P < 0.05 vs. WT. Also refer to Figure 3.2 to 3.5.
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Figure 3.2 Improved glucose tolerance, as shown by the glucose tolerance test (GTT, 1 g/kg) in the KO compared with the WT mice 
after 8 h overnight fasting at 4- and 10-month ages. Data are mean ± SE (n = 6-10), and *, P < 0.05 vs. WT. Also refer to Figure 3.1.
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Figure 3.3 Decreased plasma glucose as shown by biweekly measurements for 12 wk in the KO compared with the WT mice (2 
month old) after 8 h overnight fasting. Data are mean ± SE (n = 6), and *, P < 0.05 vs. WT. Also refer to Figure 3.1. 
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Figure 3.4 Improved glucose stimulated insulin secretion, as shown by plasma insulin concentrations after the stimulation by 1g/kg 
glucose injection in the KO compared with the WT mice after 8 h overnight fasting at 5-month ages. Data are mean ± SE (n = 6-10), 
and *, P < 0.05 vs. WT. Also refer to Figure 3.1.
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Figure 3.5 No difference in body weight, as shown by biweekly measurements for 12 wk in the KO compared with the WT mice (2 
month old) after 8 h overnight fasting. Data are mean ± SE (n = 6-10), and *, P < 0.05 vs. WT. Also refer to Figure 3.1. 
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Figure 3.6 Decreased insulin sensitivity (0.5 U/kg) in the KO mice by daily i.p. injections of the native REG3β protein (2 µg/g body 
weight) for 6 wk compared with the PBS-injected WT and KO mice. Data are mean ± SE (n = 10), and *, P < 0.05 vs PBS. Also refer 
to Figure 3.7. 
40 
80 
120 
0 15 30 60 120 Pl
as
m
a 
G
lu
co
se
 (%
 o
f  
in
iti
al
)  
Minutes 
WT 
Saline DSS 
0 
40 
80 
120 
0 50 100 150 200 
Minutes 
WT 0 
Reg 0 
Reg 6 
a
Before After 
KO Control 
 Control 
KO 2µg/g REG3β 
40 
80 
120 
0 15 30 60 120 
Minutes 
KO 
S line DSS 
*
* *
LP  
0 
40 
80 
120 
0 50 100 150 200 
Pl
as
m
a 
G
lu
co
se
 (m
g/
dL
) 
Minutes 
*, P < 0.05 vs. Saline 
a a
a
bbb
b
a a a
ab 
a
ab 
b 
a a a
a
a
b 
b b b 
b 
a vs b , P < 0.05 a vs b, P < 0.05 
b 
b b b 
b 
LP  
Zeping	Zhao	
	 25	
 
 
 
 
 
 
 
 
Figure 3.7 Decreased insulin sensitivity, as shown by ITT (0.5 U/kg), in the KO mice by daily i.p. injections of the native REG3β 
protein (2 µg/g body weight) for 2 wk compared with the PBS-injected WT and KO mice. Data are mean ± SE (n = 5), and *, P < 0.05 
vs PBS. Also refer to Figure 3.6. 
0 
100 
200 
300 
0 40 80 120 
Pl
as
m
a 
G
lu
co
se
 (m
g/
dL
) 
Minutes 
0 
100 
200 
300 
0 40 80 120 
Minutes 
*	
*	
*	
0 
80 
160 
240 
0 40 80 120 
Minutes 
Wildtype 
Knockout 
*	
*
* *
O 
T 
0 
500 
1000 
0 15 30 
In
su
lin
 (n
g/
m
L
) 
Minutes 
WT 
RegKO 
* 
* 
4 month 
70 
105 
140 
0 30 60 120 
Minutes 
2 Week 
Control 
Reg3b 2µ /g REG3β *
0 
50 
100 
150 
0 2 4 6 8 10 12 
Pl
as
m
a 
gl
uc
os
e 
(m
g/
dL
) 
Week 
Wildtype 
Knockout 
* * * 
* 
KO 
T 
2 month 4 month 10 month 
* 
KO 
 
60 
80 
100 
120 
0 30 60 120 
Pl
as
m
a 
G
lu
co
se
 
m
g/
dL
) 
Minutes 
0 Week 
40 
80 
120 
0 15 30 60 120 
Pl
as
m
a 
G
lu
co
se
 (%
 o
f  
in
iti
al
)  
Minutes 
WT 
Saline LPS 
* *
40 
80 
120 
0 15 30 60 120 
Minutes 
 
KO 
DS
*, P < 0.05 vs. WT 
*, P < 0.05 vs. WT *, P < 0.05 vs. WT 
*, P < 0.05 vs. WT 
*, P < 0.05 vs. Control *, P < 0.05 vs. Control 
*, P < 0.05 vs. Saline 
*, P < 0.05 vs. Saline 
15 
30 
45 
0 2 4 6 8 10 12 
B
od
y 
W
ei
gh
t (
g)
 
Week 
Wildtype 
Knockout O 
T 
Zeping	Zhao	
	 26	
 
 
 
 
 
 
Figure 3.8 Induced insulin resistance at 12 h after the injection of LPS (2 mg/kg), as shown by ITT, in the WT mice (1st panels) but 
not in the KO mice (2nd panels). Data are mean ± SE (n = 6), *, P < 0.05 vs. saline. Also refer to Figure 3.9. 
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Figure 3.9 Induced insulin resistance at 2 wk after the administration of 2% DSS in the drinking water, as shown by ITT, in the WT 
mice (left panel) but not in the KO mice (right panel). Data are mean ± SE (n = 6), and *, P < 0.05 vs. saline data are mean ± SE (n = 
6), *, P < 0.05 vs. WT. Also refer to Figure 3.8.
0 
100 
200 
300 
0 40 80 120 
Pl
as
m
a 
G
lu
co
se
 (m
g/
dL
) 
Minutes 
0 
100 
200 
300 
0 40 80 120 
Minutes 
*	
*	
*	
0 
80 
160 
240 
0 40 80 120 
Minutes 
Wildtype 
Knockout 
*	
*
* *
O 
T 
0 
500 
1000 
0 15 30 
In
su
lin
 (n
g/
m
L
) 
Minutes 
WT 
RegKO 
* 
* 
4 month 
70 
105 
140 
0 30 60 120 
Minutes 
2 Week 
Control 
Reg3b 2µ /g REG3β *
0 
50 
100 
150 
0 2 4 6 8 10 12 
Pl
as
m
a 
gl
uc
os
e 
(m
g/
dL
) 
Week 
Wildtype 
Knockout 
* * * 
* 
KO 
T 
2 month 4 month 10 month 
* 
KO 
 
60 
80 
100 
120 
0 30 60 120 
Pl
as
m
a 
G
lu
co
se
 
m
g/
dL
) 
Minutes 
0 Week 
40 
80 
120 
0 15 30 60 120 
Pl
as
m
a 
G
lu
co
se
 (%
 o
f  
in
iti
al
)  
Minutes 
WT 
Saline LPS 
* *
40 
80 
120 
0 15 30 60 120 
Minutes 
 
KO 
DS
*, P < 0.05 vs. WT 
*, P < 0.05 vs. WT *, P < 0.05 vs. WT 
*, P < 0.05 vs. WT 
*, P < 0.05 vs. Control *, P < 0.05 vs. Control 
*, P < 0.05 vs. Saline 
*, P < 0.05 vs. Saline 
15 
30 
45 
0 2 4 6 8 10 12 
B
od
y 
W
ei
gh
t (
g)
 
Week 
Wildtype 
Knockout O 
T 
Zeping	Zhao	
28	
Figure 3.10 Induced REG3β protein production, shown by immunoblotting, in the pancreas and intestine of WT, but not in the KO 
mice at 12 h after the injection of LPS. Data are mean ± SE (n = 6) and normalized to β-ACTIN as the loading control, *, P < 0.05 vs. 
control. Also refer to Figure 3.11 
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Figure 3.11 Elevated REG3β protein production, shown by immunoblotting, in the pancreas and intestine of WT, but not in the KO 
mice at 2 wk after the administration of 2% DSS in drinking water. Data are mean ± SE (n = 6) and normalized to β-ACTIN as the 
loading control, and *, P < 0.05 vs. control. Also refer to Figure 3.10. 
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Figure 3.12 H&E staining of the pancreas (upper panel) and intestine (lower panel) of both genotypes to show the LPS-injection (after 
12 h) induced inflammation. The image was a representation of 4 independent assays. Also refer to Figure 3.14. 
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Figure 3.13 Elevated plasma C-reactive peptide by the LPS injection (after 12 h) in both WT and KO mice. Data are mean ± SE (n = 
6) **, P < 0.01 vs. respective saline controls. Also refer to Figure 3.14;
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Figure 3.14 Dissecting the intestine of both genotypes to show the LPS-injection (after 12 h) 
induced inflammation. Arrows define the spot that demonstrates inflammation. The image 
was a representation of 4 independent assays. Also refer to Figure 3.12 and 3.13.  
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3.2 REG3β regulated INSR and AKT expression and activation 
To understand the enhanced baseline insulin sensitivity by knockout of REG3β, we 
determined the status of key insulin signal proteins in the two genotypes. qPCR and 
immunoblotting analysis illustrated that the REG3β-/- mice had 70% to 170% elevated  
gene transcripts (P < 0.05) (Fig. 3.15), 31% to 139% enhanced total protein, and 39% to 
92% increased phosphorylation of INSR and AKT (Fig. 3.16) in the liver and muscle 
compared with WT mice whereas phosphatase and tensin homolog (Pten), 
phosphoinositide 3-kinase (Pi3k), Irs1, and Irs2 were excluded for remaining little or no 
change in KO mice (Fig. S3.17). The 15 mins prior administration (i.p. injection) of 
recombinant REG3β protein from yeast to the administration of 0.25U/kg BW insulin to 
WT and KO mice suppressed (56% to 99%, P < 0.05) insulin-stimulated phosphorylation 
of INSR and AKT in the two tissues of both genotypes (Fig. 3.18). The specific inhibition 
(P< 0.05) of Insr and Akt1-3 gene expression by the exogenous 20ng/ml REG3β 
treatment for 12 hr was also shown in primary hepatocytes (54 to 83%) (Fig. 3.19) and 
HepG2 cells (Fig. 3.20).  These data indicated that the knockout of REG3β enhanced 
baseline insulin sensitivity via up-regulating the tissue expression of INSR and AKT and 
their phosphorylation. 	
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Figure 3.15 Up-regulated mRNA levels of Insr and Akt1-3 in the liver (left panel) and muscle (right panel) of the KO compared with 
the WT mice. Data are mean ± SE (n = 6-10) and normalized to the β-actin mRNA levels, *, P < 0.05 vs. WT. Also refer to Figure 
3.17. 
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Figure 3.16 Increased phosphorylated and total INSR and AKT proteins, as shown by immunoblotting, in the liver (1st panel) and 
muscle (2nd panel) of the KO compared with the WT mice. Data are mean ± SE (n = 5) and normalized toβ-Actin as the loading 
controls, *, P < 0.05 vs. WT. 
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Figure 3.17 Up-regulated mRNA levels of Insr and Akt1-3 but not Pten, Pi3k, or Irs1 and 2 in the liver (left panel) and muscle (right 
panel) of the KO compared with the WT mice. Data are mean ± SE (n = 6-10) and normalized to the β-actin mRNA levels. *, P < 0.05 
vs. WT. Also refer to Figure 3.15. 
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Figure 3.18 Inhibited phosphorylation of INSR and AKT proteins, as shown by immunoblotting, in the liver (1st panel) and muscle 
(2nd panel) of the WT mice and the liver (3rd panel) and muscle (4th panel) of the KO mice by an i.p. injection of the native REG3β 
protein (2 µg/g body weight) compared with the PBS-injected WT and KO mice at 15 min prior to the ITT (0.5 U/kg). Mice were 
killed to 3 and 7 min after the injection of insulin to collect liver and muscle samples for analysis, respectively.   Data are mean ± SE 
(n = 5) and normalized to ß-actin as the loading controls, *, P < 0.05 vs. WT. 
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Figure 3.19 Suppressed mRNA levels of Insr and Akt1-3 in the primary hepatocytes of KO mice by treating with REG3β (20 ng/mL) 
for 6 h compared with the PBS treatment. Data are mean ± SE (n = 5) and normalized to the β-actin mRNA levels, *, P < 0.05 vs. 
control. Also refer to Figure 3.20.  
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Figure 3.20 Suppressed mRNA levels of Insr and Akt1-3 in the HepG2 cells by treating with REG3β (20 ng/mL) for 6 h compared 
with the PBS treatment. Data are mean ± SE (n = 5) and normalized to the β-actin mRNA levels. *, P < 0.05 vs. control. Also refer to 
Figure 3.19. 
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3.3 The binding of REG3β to transmembrane EXTL3 stimulated the binding of 
NR3C1 to the proximate promoters of Insr and Akt1 and 2, resulting in 
transcriptional inhibition of these genes   
To explore if the elevated expression of Insr and Akt in the REG3β-/- mice was mediated 
by a common transcriptional regulation, we performed a database search by TESS 
(http://www.cbil.upenn.edu/tess/) (Schug, 2008) with the 5’ flanking region of the Insr, 
Akt1 and Akt2 gene promoters (~1kb upstream of the transcription starting site) and 
identified 9 common transcriptional factors (TF) that could potentially bind the proximate 
promoter of Insr, Akt1, and Akt2 (Akt3 was excluded for little involvement in insulin 
sensitivity). Although 5 of these TFs [Ccaat-enhancer-binding proteins beta (C/ebpb, 
45%), Nr3c1 (47%), hepatocyte nuclear factor-3 beta (Hnf3b, 2.7-fold), wilms tumor 
protein (Wt1, 40%) and Ccaat-enhancer-binding proteins delta (C/ebpd, 80%)] showed 
genotype differences (P < 0.05) in the hepatic mRNA abundance (Fig. 3.21), only the 
change of glucocorticoid receptor Nr3c1 mRNA was reversed (18%, P < 0.05) by the 
20ng/ml REG3β treatment in the hepatocytes of REG3β-/-mice (Fig. 3.22). Therefore, we 
chose NR3C1 as the most viable candidate for mediating the impacts of REG3β on Insr 
and Akt1,2. To map the binding sites of NR3C1 in their promoters, we constructed a 
series of luciferase reporter plasmids with DNA fragments of Akt1 and 2 (-1,000 to 0 bp) 
and Insr (-1100 to 0 bp) genes and transfected them into HepG2 cells. Based on their 
responses to the transcriptional inhibition by 12 hr 20ng/ml REG3β treatment, we 
narrowed down the binding regions in the Akt1 and 2 promoters to -250 to 0 bp (up to 
90% inhibition, P < 0.05) and Insr promoter to -1100 to -500 bp (71% inhibition, P < 
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0.05) (Fig. 3.23). Subsequent ChIP assays to test an actual binding of Nr3c1 to the 
Insr/Akt1/Akt2 proximal promoter with designed three or four sets of primers that 
spanned the 5’-flanking region of Insr/Akt1/Akt2 (-1,100/-1000 to 0 bp) (Appendix, Table 
1) and isolated chromatin from WT and KO hepatocytes revealed the actual binding in
the proximate promoter of Insr at -1100/-761 bp, Akt1 at -760/-521 and -280/-1 bp, and 
Akt2 at -280/-1 bp (dotted circle) (Fig. 3.24). Knocked down (80%, P< 0.05) of Nr3c1 
enhanced (P < 0.05) mRNA levels of Insr (24%), Akt1 (84%), and Akt2 (59%) (Fig. 3.25). 
These enhancements in HepG2 cells were similar to the knockout effects of REG3β on 
the expression of these genes in the liver of mice, which illustrated importance of the 
tested NR3C1 binding in the proximate promoters of the three genes in mediating the 
inhibition of their transcription by REG3β.  
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Figure 3.21 Relative mRNA levels of 5 common transcription factors that potentially bind the 
proximate promoters of Insr and Akt1,2 in the liver of WT and KO mice. Data are mean ± SE 
(n = 6-7) and normalized to the β-actin mRNA levels, *, P < 0.05 vs. WT. 
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Figure 3.22 Reversing mRNA levels of Nr3c1 by treating with REG3β (20 ng/mL) for 6 
h in primary hepatocytes of the KO mice. Data are mean ± SE (n = 5) and normalized to
the β-actin mRNA level, *, P < 0.05 vs. control. 
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Figure 3.23 Suppressed transcription activity of the promoter of Insr (-500bp to -1100bp) (upper 
panel) and Akt1 (middle panel) and 2 (0bp to -250bp) (lower panel) in the HepG2 cells 
transfected with luciferase vector containing different length promoter region of Insr, Akt1 and 
Akt2 for 48 h by treating with REG3β (20 ng/mL) for 8 h. Data are mean ± SE (n = 5), and *, P < 
0.05 vs. control. Also refer to Figure 3.24 
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Figure 3.24 Stimulated binding of NR3C1 to the proximate promoters of Insr, Akt1 and 
Akt2 by REG3β (P1-P4 represent primer pairs cover different sequence of promoters of 
Insr, Akt1, and Akt2) as shown by the stronger signal on the left of the fourth [primer set 
4 of Insr (-1100/-761)], fifth [primer set 1 of Akt1 (-760/-521)], seventh [primer 3 (-280/-
1) of Akt1], and last boxes [primer set 3 of Akt2 (-280/-1)] in frame). Chromatin was
isolated from the hepatocytes of WT and KO mice after fixation with 4% 
paraformaldehyde, and pulled down with an anti-NR3C1 antibody. The precipitate was 
analyzed by PCR. The binding affinity was shown by the intensity of the amplified PCR 
band signal. The image was a representation of 3 independent assays. Also refer to Figure 
3.23.  
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Figure 3.25 Elevated mRNA levels of Insr and Akt1 and 2 by knocking out of Nc3r1 in 
the HepG2 cells. Data are mean ± SE (n = 5) and normalized to the β-actin mRNA level, 
*, P < 0.05 vs. control. 
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To link the endocrine-like, extracellular REG3β to the action of NR3C1 in the 
transcriptional inhibition of Insr and Akt1,2, we conducted an exhaustive literature search 
and found EXTL3 (a glycosyltransferase that regulates the biosynthesis of heparan 
sulfate) (Busse et al., 2007) as the most promising candidate. This was because: 1) 
EXTL3 is be able to bind the human homologue of REG3β: hREG3α and REG1α (Van 
Ba et al., 2012; Wu et al., 2016b); and 2) heparan sulfate proteins, produced by the 
catalysis of EXTL3 (Busse et al., 2007), could activate NR3C1 via stepwise interactions 
with fibroblast growth factor and fibroblast growth factor receptor complex to activate 
ERK1/2 (Galanternik et al., 2015), the complex of tau 1 transactivation domain of 
NR3C1(Dahlmanwright et al., 1994) with cAMP response element binding protein 
(Almlof et al., 1998). To test whether REG3β bound EXTL3, we overexpressed EXTL3 
in HepG2 cells (Fig. 3.26) and showed a co-IP of the two proteins by incubating the 
homogenates of HepG2 cells with or without EXTL3 with native REG3β produced in P. 
pastoris (Appendix, Table 3). The bound complex was pulled down using an EXTL3 
antibody and the physical binding between these two proteins was verified by 
immunoblotting the precipitates against a REG3β antibody (Fig. 3.27). Their interaction 
was confirmed by the consistent result of dual-fluorescent co-localization in the cells as 
we generated native REG3β-EGFP in HEK293T cells (EGFP protein was used as a 
control) and then added these exogenous proteins into the culture media of HepG2 cells 
overexpressing EXTL3-mCherry. After the incubation, cells were washed and observed 
under microscope. Consistently, only the REG3β-EGFP treatment yielded yellow 
fluorescence, which is resulted from an overlap of the green (REG3β-EGFP) and the red 
fluorescence (EXTL3-mCherry) on the cell surface. This effect was not seen with the 
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EGFP control. Furthermore, this binding could be inhibited by the addition of EXTL3 
antibody into the reaction (Fig. 3.28). Thereafter, we performed a knockdown of Extl3 in 
the HepG2 cells that duplicated the impacts of REG3β knockout in the tissues: 19-79% 
upregulation of Insr and Akt1,2 mRNA, and decreased heparan sulfate proteins 
production (Fig 3.29 and 3.30). More directly, knockdown of Extl3 totally blocked the 
effects of exogenous REG3β on Insr, Akt1,2, and Nr3c1 (Fig 3.32). Altogether, we 
proved the binding of REG3β to EXTL3 to initiate the transcriptional inhibition of Insr 
and Akt1,2.  
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Figure 3.26 Overexpressed EXTL3 protein in the HepG2	cells, as shown by 
immunoblotting. Image was a representation of 3 independent experiments. Also refer to 
Figure 3.27. 
EXTL3 
EXTL3 OE Control 
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Figure 3.27 A specific co-immunoprecipitation of REG3β and EXTL3 proteins. After 
EXTL3 was overexpressed in the HepG2 cells for 48 h, the homogenate was incubated 
with the native REG3β-EGFP protein produced in yeast. The binding complex was 
precipitated with the anti-EXTL3 antibody, and the precipitate was immunoblotted 
against anti-REG3β antibody. The image was a representation of 3 independent assays. 
Also refer to Figure 3. 26.	
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Figure 3.28 Binding of exogenous REG3β-EGFP (green fluorescence) overexpressed in HEK293 T cells and added in the media to 
EXTL3-mCherry (red fluorescence) overexpressed in HepG2 cells for 48 h on the cell surface yielded yellow fluorescence (the 3rd 
box), resulting from the co-localization of the two proteins. This binding was not induced by either adding EGFP or in cells 
overexpressing mCherry, but was blocked by the EXTL3 antibody added in the media (the 4th box). The image was a representation of 
3 independent assays. 
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Figure 3.29 Blocked responses of heparan sulfate proteoglycans on the cells surface to 
the treatment of REG3β (20 ng/mL for 6 h) in the HepG2 cells by the knock down of 
EXTL3. Data are mean ± SE (n = 5), and data with different letters differ. Also refer to 
Figure 3.30. 
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Figure 3.30 Blocked responses of GAG chains on the cells surface to the treatment of 
REG3β (20 ng/mL for 6 h) in the HepG2 cells by the knock down of EXTL3. Data are 
mean ± SE (n = 5), and data with different letters differ. Also refer to Figure 3.29 and 
3.32.  
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Figure 3.31 Elevated mRNA levels of Insr and Akt1-2 in the HepG2 cells by knocking 
down EXTL3. Data are mean ± SE (n = 5) and normalized to the β-actin gene mRNA 
level. *, P < 0.05 vs. control. Also refer to Figure 3. 32. 
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Figure 3.32 Blocked responses of Insr, Akt1-2 and Nr3c1 mRNA levels to the treatment of REG3β (20 ng/mL for 6 h) in the HepG2 
cells by the knockout of EXTL3. Data are mean ± SE (n = 5) and normalized to the β-actin mRNA levels. Data with different letters 
differ (P < 0.05). Also refer to Figure 3.30 and 3.31. 
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3.4 The binding of REG3β to transmembrane CXCR4 activated SOCS3, leading to 
subsequent inhibition of INSR and AKT phosphorylation 
To reveal mechanisms for the ablated IR induced by LPS and DSS-mediated 
inflammation in the REG3β-/- mice, we determined effects of these compounds on 
insulin-stimulated phosphorylation of tissue INSR and AKT. While LPS abolished or 
decreased (47% to 100%, P < 0.01) P-INSR and(or) P-AKT  in the liver and muscle of 
WT, it affected little or even enhanced their phosphorylation in these tissues of REG3β-/-
mice (Fig. 3.33). As P-INSR and P-AKT in inflammation are largely decreased by 
SOCS3 (Nieto-Vazquez et al., 2008), we followed up its responses to the LPS treatment. 
While hepatic SOCS3 was enhanced (P < 0.05, 42%) in the WT by LPS, no change was 
seen in the REG3β-/- mice (Fig. 3.34). Comparatively, responses of c-Jun N-terminal 
kinase (P-JNK) and P38 MAP kinase (P38) that were also reported to affect the 
phosphorylation of INSR and AKT (Nieto-Vazquez et al., 2008) were mixed (Fig. 3.34). 
Because SOCS3 was shown to be directly stimulated by CXCR4 (Takekoshi et al., 2013), 
a well-known transmembrane inflammatory protein (Wescott et al., 2016) that was 
induced by LPS (Fig. 3.34), in the presence of its ligand CXCL12, and the 
CXCL12/CXCR4 complex was speculated as the target of REG3β in cancer cells (Loncle 
et al., 2015), we hypothesized that lack of this putative binding might block the 
inflammation-induced IR in the REG3β-/- mice.  
We performed cross-linking co-IP using extracellular REG3β-EGFP overproduced in 
HepG2 cells to bind the intrinsic CXCR4 protein on the surface of the HepG2 cells in the 
presence of added CXCL12-His overexpressed in P. pastoris (Appendix, Table 3) in the 
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media compared with non-overproduced REG3β-EGFP cells. After the target binding, the 
complex was cross-linked with 1mM disuccinimidyl suberate and the complex were 
pulled down by the EGFP affinity beads, the physical interactions among these three 
proteins were verified by immunoblotting using three antibodies against REG3β, 
CXCR4, and CXCL12-His-tag, respectively (Appendix Table 3, Fig. 3.35). This binding 
was clearly dependent on the level of REG3β-EGFP in the media and was only seen 
when both the REG3β-EGFP protein and EGFP affinity beads were added into the 
mixture. In addition, the putative binding between the overexpressed mCherry-CXCR4 in 
HepG2 cells with the added REG3β-EGFP overexpressed in HEK293 T cells in the 
media was confirmed by the consistent result of the dual-fluorescent co-localization 
assay, as only the REG3β-EGFP treatment yielded yellow fluorescence resulted from an 
overlap of the green (REG3β-EGFP) and the red fluorescence (CXCR4-mCherry) on the 
cell surface, whereas the EGFP or mCherry protein itself did not show any positive signal 
and this binding was blocked by CXCR4 antibody (Fig. 3.36 and 3.37). Specificity of this 
binding was shown by the negative outcome with another inflammation-related protein 
GP130 that was also suggested to bind to REG3β (Loncle et al., 2015) (Fig. 3.38). 
Therefore, we proved our hypothesis that the inflammation-elevated REG3β could bind 
CXCL12/CXCR4 complex to stimulate SOCS3, inhibiting phosphorylation of INSR and 
AKT. 
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Figure 3.33 Abolished or decreased insulin-stimulated phosphorylation of INSR and 
AKT protein at 12 h after the injection of LPS (2 mg/kg), shown by immunoblotting, in 
the liver (upper panel) and muscle (lower panel) of WT mice but not in the KO mice (2-
month old). Data are mean ± SE (n = 5) and normalized toβ-Actin as the loading 
control, *, P < 0.05 vs. WT/KO control.
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Figure 3.34 Elevation of SOCS3 and CXCR4 and mixed responses of other 4 
inflammation-IR-related factors in amounts of phosphorylated or total proteins at 12 h 
after the injection of LPS (2 mg/kg), shown by immunoblotting, in the liver of the WT, 
but not in the KO mice. Data are mean ± SE (n = 6) and normalized toβ-ACTIN as the 
loading control. Data with different letters differ, P < 0.05. 
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Figure 3.35 A specific co-immunoprecipitation of REG3β, CXCR4, and CXCL12 
proteins. After REG3β-EGFP was overexpressed extracellularly in the HepG2 cells for 
48 h and bound with intrinsic CXCR4 in the presence of CXCL12-His (produced in 
yeast) added into the medium, the binding complex was cross-linked by 1 mM 
disuccinimidyl suberate (DSS) for 30 min. The cells were homogenized and the binding 
complex was precipitated with EGFP affinity beads. The precipitate was immunoblotted 
against anti-CXCR4, His, and REG3β antibodies. The image was a representation of 3 
independent assays. Also refer to Figure 3.38.	
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Figure 3.36 Binding of added REG3β-EGFP (green fluorescence) overexpressed in HEK293 T cells in the media to CXCR4-mCherry 
(red fluorescence) overexpressed in HepG2 cells for 48 h on the cell surface, as shown by the yellow fluorescence (the 3rd panel) 
resultant from the co-localization of REG3β-EGFP and CXCR4-mCherry. The binding was not induced by either EGFP or in cells 
overexpressing mCherry, but was blocked by the CXCR4 antibody in the media (the 4th panel). The image was a representation of 3 
independent assays. Also refer to Figure 3.38 
Zeping	Zhao	
63	
Figure 3.37 Binding of added REG3β-EGFP (green fluorescence) overexpressed in HEK293 T cells in the media to CXCR4-mCherry 
(red fluorescence) overexpressed in HepG2 cells for 48 h on the cell surface, as shown by the yellow fluorescence (the 3rd panel)
resultant from the co-localization of REG3β-EGFP and CXCR4-mCherry. The binding was not induced by either EGFP or in cells 
overexpressing mCherry, but was blocked by the CXCR4 antibody in the media (the 4th panel). The image was taken at 2 h after the 
binding was induced and was a representation of 3 independent assays. Also refer to Figure 3.36. 
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Figure 3.38 Failure to precipitate GP130 by REG3β proteins. After REG3β-EGFP was 
overexpressed extracellularly in the HepG2 cells for 48 h and incubated with intrinsic 
GP130 in the presence of IL-6-His (produced in yeast) added into the medium, the 
intended binding complex was cross-linked by 1 mM disuccinimidyl suberate (DSS) for 
30 min. The cells were homogenized and the binding complex was precipitated with 
EGFP affinity beads. The precipitate was immunoblotted against anti-GP130, His, and 
REG3β antibodies. The image was a representation of 3 independent assays. Also refer to 
Figure S3C. Also refer to Figure 3.33 and 3.35.  
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3.5 Pre-clinical testing of manipulating REG3β and its human homolog hREG3α  on 
insulin sensitivity and effects of 5 commonly-used anti-inflammatory drugs on tissue 
REG3β protein production  
To explore the physiological relevance and clinical potential of improving insulin 
sensitivity by removing REG3β, we injected (ip) its antibody into mice with a strong IR 
(McClung et al., 2004). Compared with the vehicle control, the antibody injections (every 
other day for 2 wk) improved (16%, P < 0.05) insulin sensitivity (Fig. 3.39) and 17% 
decreased fasting blood glucose (Fig. 3.40), without affecting body weights (Fig. 3.41) 
compared with the PBS-injected control. While REG3α is considered the human 
homolog of murine REG3β in humans, to our best knowledge, solid proof is still lacking. 
Therefore, to test the potential of identifying REG3α as the target in human to improve 
insulin sensitivity, we inject (i.p.) both WT and REG3β-/- mice with hREG3α, 15 min 
prior to ITT.  In contrast to removing REG3β, the 4 µg/g of body weight hREG3α 
injecting, decreased 15% (P < 0.05) insulin sensitivity in both genotypes (Fig. 3.42 and 
Fig. 3.43) than the PBS-injected mice. This illustrated similar functions and the clinical 
potential of neutralizing both REG3β and hREG3α for improving insulin sensitivity. To 
test if responses of REG3β could help explain the conflicting effects of anti-inflammatory 
drugs on IR (Buren et al., 2002; da Silva et al., 2018; Ford et al., 2015), we treated the 
WT with 5 commonly-used AIT drugs after the LPS challenge (Buren et al., 2002; da 
Silva et al., 2018; Ford et al., 2015). Actual effects of these 5 drugs on IR were 
remarkably consistent with their ability to regulate REG3β protein (Fig. 3.44): 0.12 
mg/kg body weight 6 hr treatment of DEX aggravates IR elevated the protein in pancreas 
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(P < 0.05); 5 mg/kg bodyweight 2 wk treatment of sulindac and 40mg/kg body weight 1 
hr treatment of statin do not affect IR failed to change the protein expression induced by 
2mg/kg body weight LPS treatment; and 81mg/kg body weight 1 hr treatment of aspirin 
and 40mg/kg body weight 2wk treatment of ibuprofen that alleviate IR decreased the 
protein expression induced by 2mg/kg body weight LPS treatment. 	
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Figure 3.39 Enhanced insulin sensitivity, as shown by ITT (0.5 U/kg), in the insulin resistant mice by i.p. injections of anti-REG3β 
antibody (0.4 µg/g, every other day for 2 wk) compared with the pre-immune serum-injected control mice. Data are mean ± SE (n = 
10), and *, P < 0.05 vs pre-immune serum control. Also refer to Figure 3.40 and 3.41.   Pancreas REG3β 
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Figure 3.40 Decreased plasma glucose in the insulin resistant mice by i.p. injections of 
anti-REG3β antibody (0.4 µg/g BW, every other day for 2 wk) compared with the pre-
immune serum-injected control mice after 8 h overnight fasting. Data are mean ± SE (n = 
10), and *, P < 0.05 vs pre-immune serum controls. Also refer to Figure 3.39. 
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Figure 3.41 Lack of difference in body weight in the insulin resistant mice by i.p. 
injections of anti-REG3β antibody (0.4 µg/g BW, every other day for 2 wk) compared 
with the pre-immune serum-injected control mice after 8 h overnight fasting. Data are 
mean ± SE (n = 5), and *, P < 0.05 vs. pre-immune serum controls. Also refer to Figure 
3.39. 
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Figure 3.42 Decreased insulin sensitivity, as shown by ITT (0.5 U/kg), in the WT and KO mice by a single i.p. injection of the native 
REG3α (4 µg/g body weight) at 15 min prior to ITT, compared with the PBS-injected controls. Data are mean ± SE (n = 10), and *, P 
< 0.05 vs the PBS controls. Also refer to Figure 3.43. 
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Figure 3.43 Decreased insulin sensitivity, as shown by ITT (0.5 U/kg), in the WT and 
KO mice by a single i.p. injection of the native REG3α (2 or 4 µg/g BW) at 15 min prior 
to ITT, compared with the PBS-injected controls. Data are mean ± SE (n = 10), and *, P 
< 0.05 vs the PBS controls. Also refer to Figure 3.42. 	
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Figure 3.44 Effects of 5 commonly-used anti-inflammatory drugs on the REG3β protein production, shown by immunoblotting, in the 
pancreas and intestine of WT mice. Data are mean ± SE (n = 6) and normalized toβ-ACTIN as the loading control, *, P < 0.05 vs. 
controls.
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CHAPTER FOUR 
DISCUSSION 
4.1 Discussion 
Our most exciting discovery is that knockout of REG3β enhanced baseline insulin 
sensitivity and blocked the inflammation-induced IR in the mice. This finding enables 
three major conceptual breakthroughs: 1) REG3β acted as a novel, potent, and negative 
determinant of the baseline insulin sensitivity; 2) REG3β was required for the systemic 
inflammation to induce IR; and 3) REG3β functioned beyond regeneration and anti-
inflammation. These breakthroughs will have significant implications to advance the 
broad field of biomedical science related to diabetes, inflammation, and regeneration. 
Although several previous studies implied a potential association of REG3β and hREG3α 
with IR (Calderari et al., 2014; Wu et al., 2016a; Xiong et al., 2016), our study provides 
the first direct and two-way (reciprocal) evidences to reveal its potent role in controlling 
baseline insulin sensitivity, and will enable a completely new therapy prospect and target 
to improve IR in diabetes. More strikingly, demonstrating the essentiality of REG3β, a 
recognized anti-inflammatory protein (Aden et al., 2016), for the LPS and DSS-induced 
IR may drastically revise the current theory on the inflammation-induced IR (Ghorpade et 
al., 2018; Li et al., 2015; Tian et al., 2016). This indicates that the inflammation-induced 
IR requires a co-existence or stimulation of anti-inflammatory proteins such as REG3β 
with the inflammatory cytokines and interleukins protein (Aden et al., 2016; Jorgensen et 
al., 2013; Kim et al., 2004; Matsubara et al., 2012). Thereby, this type of co-stimulation 
or existence may help explain why not all types of inflammation necessarily induce IR 
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(Tian et al., 2016), and why altering only inflammatory factors such as TNFα (Ventre et 
al., 1997) and IL-1R antagonist (Larsen et al., 2009)  fails to improve insulin sensitivity. 
Conversely, anti-inflammatory proteins such as REG3β may serve as a better target or a 
simultaneous target with inflammatory factors to treat the inflammation-induced IR. 
Revealing a new role of REG3β in insulin sensitivity and inflammation-induced IR, in 
addition to the previously reported functions in tissue regeneration (Lorchner et al., 
2015), cancer (Liu et al., 2015) and anti-microbe/inflammation (Aden et al., 2016; Miki 
et al., 2012), may suggest a unique, fundamental position for this endocrine-like molecule 
to link or coordinate various metabolic processes. 
Our study unveils the binding of REG3β to two transmembrane proteins for exerting its 
long and short-term effect on the baseline insulin sensitivity and the inflammation-
induced IR, respectively (Fig. 7). The long-term effect was conferred by binding to 
EXTL3 to activate NR3C1 that bound the proximate promoters of Insr, Akt1, and Akt2 to 
inhibit the transcription of these genes. Our work carefully elucidated how knockout of 
REG3β removed this inhibition, leading to the elevated transcripts and proteins of INSR 
and AKT. Because previous research showed only the binding of FOXO1 in the Insr 
promoter in the absence of insulin (Puig and Tjian, 2005). However, FOXO1 was 
reported had dual functions in promoting insulin sensitivity as well as stimulating hepatic 
lipid synthesis and hepatic glucose production (Matsumoto et al., 2006; Nakai et al., 
2002). Thus, the application of FOXO1 as a promising therapeutic target to treat insulin 
resistance is limited. Previous research showed that NR3C1 was associated with GSIS 
(van Raalte et al., 2012) and insulin level (van Rossum et al., 2002). Moreover, the 
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inhibition of glucocorticoids on insulin sensitization is documented (Geer et al., 2014). 
Even though ChIP assay identified several target genes of GR including insulin signaling 
transactivation genes (Wang et al., 2004), binding of GR to the promoter of 
Insr/Akt1/Akt2 has never been reported. The binding of NR3C1, activated by the 
interaction of REG3β and EXTL3, to the proximate promoters of Insr/Akt1/Akt2, 
represents a rather new mechanism for the transcriptional regulation of key insulin signal 
proteins. This also explains the reported association of NR3C1 and its ligand-
glucocorticoids with IR (Kang et al., 2015).  
At the same time, the short-term or immediate effect was mediated by binding to CXCR4 
to stimulate SOCS3 that subsequently inhibited the insulin-stimulated phosphorylation of 
INSR and AKT. Because both REG3β and CXCR4 could be induced by glucocorticoids 
(Luo et al., 2013; Wang et al., 1998) and inflammatory stimulants such as LPS (this 
study), illustrating the actual binding of CXCR4/CXCL12 to REG3β not only fills the 
previous knowledge gap (Buren et al., 2002; da Silva et al., 2018; Ford et al., 2015; 
Larsen et al., 2009; Ventre et al., 1997) but also offers a structure mechanism to link their 
functions. Previously, GP130 and CXCL12/CXCR4 complex were speculated as the 
target of REG3β in cancer cells (Loncle et al., 2015) but the supporting binding 
experimental data were not demonstrated. Our study represents the first attempt to reveal 
that CXCR4 as the tranmembrane protein and receptor for CXCL12 physically interact 
with REG3β and no interaction was observed between GP130 and REG3β even though 
GP130 is proved as a target of REG3β.  
Zeping	Zhao	
76	
Tremendous clinical potential is derived from our research. The potent inhibition of 
baseline insulin sensitivity by REG3β, the improved insulin sensitivity by its antibody in 
the IR mice, and the similar function of the human homologue hREG3α consistently 
point out not only the confirmation of homologues between REG3β and hREG3α but 
also REG3β/hREG3α as a powerful, new therapy target to treat IR in diabetes as many 
beneficial drugs were limited by severe side effects including nausea (Fujii et al., 2012), 
vomiting (Merrill et al., 2010), risk of organ bleeding (Garcia Rodriguez et al., 2016). 
The block of inflammation-induced IR by the knockout of REG3β provides a new, 
effective strategy to neutralize the protein in preventing and treating the inflammation-
related IR and diabetes that afflicts 10-20% the population (Spranger et al., 2003). 
Illustrating the relationship between their regulation of tissue REG3β and their impact on 
the inflammation-induced IR of five commonly used anti-inflammatory drugs not only 
helps explain the previously conflicting results in the clinic (Buren et al., 2002; da Silva 
et al., 2018; Ford et al., 2015), but also will guide the selection of these drugs in treating 
inflammation, in particular diabetic patients (Pollack et al., 2016).  
4.2 Conclusion 
In summary, our research reported an anti-inflammatory protein-REG3β is the key 
mediator of the inflammation-induced IR and its homologue in humans might be a novel 
target for ameliorating IR in type 2 diabetic patients clinically. Our research 
demonstrated REG3β inhibits the phosphorylation level of the insulin signaling pathway 
by binding to CXCL12/CXCR4 to activate SOCS3, and inhibits transcription of insulin 
Zeping	Zhao	
77	
signaling pathway genes by binding to EXTL3 to activate the binding of NR3C1 with 
Insr/Akt1/Akt2 promoter (Fig. 7). This discovery completes the traditional inflammation-
IR model and provides a novel potential target to solve the inconsistency problem of 
AITs on IR and to treat similar human disorders of IR. 
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Figure 4.1 Postulated mechanistic scheme for impacts on insulin sensitivity mediated by 
the inflammation/REG3β/EXTL3/CXCR4/NR3C1/SOCS3 cascade in the liver. After 
inflammation induces the expression of REG3β in the pancreas and intestine, the secreted 
REG3β binds to transmembrane CXCR4 and its ligand CXCL12, leading to an acute 
inhibition of INSR and AKT phosphorylation. Meanwhile, the secreted REG3β binds to 
transmembrane EXTL3 and in turn stimulates the binding of NR3C1 to the proximate 
promoters of Insr and Akt1 and 2, resulting in transcriptional inhibition of these genes. In 
contrast, the lost binding of REG3β to EXTL3 and CXCR4 in the REG3β-deficient mice   
improves baseline insulin sensitivity and blocks the inflammation-induced insulin 
resistance. 
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TABLES
Table 1. Primers used for various purposes in this study 
Gene Name Forward ( 5'---3' ) Reverse ( 5'---3' ) 
Primers for Q-PCR analysis of insulin signal, electron transportation chain and 
cell proliferation and apoptosis gene 
mInsr GCCACTGTCATCAATGGGCAGTTT AGATAGAAGTTGCGACAGGCCACA 
hInsr TCCATTTCTGGGAATGAAGC GAGAGGAAACGCCACAAGAG 
mAkt1 TATTGGCTACAAGGAACGGCCTCA TGTCTTCATCAGCTGGCATTGTGC 
hAkt1 CATCACACCACCTGACCAAG CTCAAATGCACCCGAGAAAT 
mAkt2 TAGCAGAATGCCAGCTGATG CTTGTAATCCATGGCGTCCT 
hAkt2 GAGGTCATGGAGCACAGGTT CTGGCCGAGTAGGAGAACTG 
mAkt3 AGGACCGCACACGTTTCTAT TCTGGTGTGCCACAGAATGT 
hAkt3 GTTCGAGAGAAGGCAAGTGG TCGCCCCCATTAACATATTC 
Irs1 CCCACAGCAGATCATTAACC AGAGACGAAGATGCTGGTGC 
Irs2 GCCTGGGGATAATGGTGACTA TCCATGAGACTTAGCCGCTTC 
Pi3k AATAGGTTACAGTGCGGGCCGTAT CAGTTTCCTTGGCTTTGCTCGGTT 
Pten TGGATTACAGACCCGTGGCA ACAAACTGAGGATTGCAAGTTCC 
hExtl3 TCACGCTCTTTGTCATCCTG GCTCTTCACTCACCGACTCC 
Tnfα CGTCAGCCGATTTGCTATCT TGGAAGACTCCTCCCAGGTA 
Nfkb1 TTGGGAGAAGGCTGGAGAAG TGAACACAGGCTCATACGGT 
P65 CACCGGATTGAAGAGAAGCG AGTTGAGTTTCGGGTAGGCA 
Il1β CCCAAGCAATACCCAAAGAA GCTTGTGCTCTGCTTGTGAG 
Ikbkβ TCAGTGCATCTCAGACAGCA TACAGCTGACACTTTCCGGT 
Il6 AGACTTCCATCCAGTTGCCT CAGGTCTGTTGGGAGTGGTA 
Il17 CAAACACTGAGGCCAAGGAC 
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GAGGTAGTCTGAGGGCCTTC 
Il22 TCCAACTTCCAGCAGCCATA TAGCACTGACTCCTCGGAAC 
mβ-Actin TCATGAAGTGTGACGTGGACATC CAGGAGGAGCAATGATCTTGATCT 
hβ-Actin GGACTTCGAGCAAGAGATGG AGCACTGTGTTGGCGTACAG 
Primers for Q-PCR analysis of transcriptional factor genes with binding 
domains in the proximal promoter of Insr and Akt1-3 genes  
C/ebpd ATCGACTTCAGCGCCTACAT CTAGCGACAGACCCCACAC 
C/ebpβ CAAGCTGAGCGACGAGTACA AGCTGCTCCACCTTCTTCTG 
mHnf3b GACATACCGACGCAGCTACA GGCACCTTGAGAAAGCAGTC 
hHnf3b CTACGCCAACATGAACTCCA CGGTAGAAGGGGAAGAGGTC 
mNr3c1 AGGCCGCTCAGTGTTTTCTA TACAGCTTCCACACGTCAGC 
hNr3c1 TACCCTGCATGTACGACCAA TCCTTCCCTCTTGACAATGG 
Wt1 AGTTCCCCAACCATTCCTTC CATTCAAGCTGGGAGGTCAT 
PCR primers used to create plasmid for luciferase assayb 
Insr P1 (-250/0) AAAGGTACCAGCTAGTCCGTCGGTCCGC AAAGCTAGCGGCTCGATTTTGGCTTGG 
Insr P2 (-500/0) GGGGGTACCTCTGAAACTGGAGGAGAC AAAGCTAGCGGCTCGATTTTGGCTTGG 
Insr P3 (-1000/0) AAAGCTAGCGGTAGAGAAAGGATCTGT AAAGCTAGCGGCTCGATTTTGGCTTGG 
Insr P4 (-1100/0) AAAGGTACCTCAGAGATGTCCACCTGC AAAGCTAGCGGCTCGATTTTGGCTTGG 
Akt1 P1 (-250/0) GGGGGTACCTTTACAGACGGGGAAACT AAAGCTAGCCGCGGGGAGGAAATCCA 
Akt1 P2 (-500/0) AAAGGTACCCCCACCTCCAACTGACCT AAAGCTAGCCGCGGGGAGGAAATCCA 
Akt1 P3 (-1000/0) GGGGGTACCCTGAAAATAAAAATGCTC AAAGCTAGCCGCGGGGAGGAAATCCA 
Akt2 P1 (-250/0) GGGGGTACCTGAAAAGGAAACCCCTCC AAAGCTAGCAGACAACTTTGGGCCTGT 
Akt2 P2 (-500/0) GGGGGTACCCTGGAATATGTACGATGA AAAGCTAGCAGACAACTTTGGGCCTGT 
Akt2 P3 (-1000/0) AAAGGTACCCCCTATGAGAGAGGAGGG AAAGCTAGCAGACAACTTTGGGCCTGT 
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PCR primers used for ChIP assayc 
 Insr P1 (-280/-1) TTGGGTGTTTATGTTACACTGGT AGGGAAGGGACTGTGCG 
 Insr P2 (-520/-281) CTCCAGACCTTTAAATTGGA CAACTCTAAGACTCACCTG 
 Insr P3 (-760/-521) TGGTAGCATAGGCTGTAAAGA A CACACTCTAGATCTCCGCCA 
Insr  P4 (-1100/-761) TGCTAGTGAATGGCTTTCTT AATGTCTTACGAGATTCTCC 
Akt1 P1 (-760/-521) TCGCCTATCCCCCAACCCAC CTCCTACTTCCCCCATCCCG 
Akt1 P2 (-520/-281) AGGAGGAGTTGGGGGCCTGG CAGCCACGCCCCATACCCTT 
Akt1 P3 (-280/-1) GAGAGGAGAGTGAGTTCTTCTCC GGCCAGCCTCAGCAGTTC 
Akt1 P4 (-1000/-761) GAAGAGGATATTCTAATGTGGG TCTGCCTTCTGAGCAATAGG 
Akt2 P1 (-760/-521) AGCAGGCAGATCTCTGAGTTC GCAGGCCAGAAGAGGGCATC 
Akt2 P2 (-520/-281) GCAGATCAGAGCACTCATACAT CTCACAGGGGTTGCCTAAGA 
Akt2 P3 (-280/-1) AGGTTCCCAAGTGAAGAACCGC GGCAGGCTCAAGGCAGCGCG 
Akt2 P4 (-1000/-761) GATCTCATTACGGGTGGTTG CTCCTTCTGGGTCCACACTT 
Primers used to create exogenous Reg3ß/Cxcl12/Il-6 
pPICZαA-Reg3ß CCGGAATTCGAAGACTCCCTGAAGAAT GCTCTAGAAAACCAGTAAATTTGCAGAC 
pPICZαA-Cxcl12 AAAGAGCTCGACGCCAAGGTCGTC AAACTCGAGGTTTTTCCTTTTCTGGGCAG 
pPICZαA-Il-6 AAAGAGCTCAAGTTCCTCTCTGCAAGA AAACTCGAGGGTTTGCCGAGTAGATCT 
Primers used to create plasmid for AP-TAG binding and fluorescent-TAG 
binding assay 
AP-TAG Reg3β GCTAGAATTCATGCTGCCTCCAACAG TTGTTCTAGACCACCAGTAAATTTGCA 
pmCherry-Extl3 AAACTCGAGACAGGCTATACCATGTTG TGGAAGCTTCTAGATGAACTTGAAGCACT 
pmCherry-Cxcr4 AAACTCGAGGAACCGATCAGTGTGAGT AAAGTCGACTTAGCTGAAGTGAAAACT 
pcDNA-Reg3-EGFP AAAAAGCTTATGCTGCCTCCAACACC GGGGGTACCACCAGTAAATTTGCAGAC 
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aAbbreviations: Akt1, AKT serine/threonine kinase 1; Akt2, AKT serine/threonine kinase 
2; Akt3, AKT serine/threonine kinase 3; AP, alkaline phosphatase;ß-Actin, beta-actin; 
C/ebpβ, CCAAT/enhancer binding protein beta; C/ebpd, CCAAT/enhancer binding 
protein delta; Cxcl12, C-X-C motif chemokine ligand 12; Cxcr4, C-X-C motif chemokine 
receptor 4; EGFP, enhanced green fluorescent protein; Extl3, exostosin like 
glycosyltransferase 3; Hnf3b, Forkhead Box A2; Ikbkβ, inhibitor of nuclear factor kappa 
B kinase subunit beta; Il1β, interleukin 1β; Il-6, interleukin 6; Il17, interleukin 17; Il22, 
interleukin 22; Insr, insulin receptor; Irs1, insulin receptor subunit 1; Irs2, insulin 
receptor subunit 2; mCherry, mCherry fluorescent protein; Nfkb1, nuclear factor kappa B 
subunit 1; Nr3c1, glucocorticoid receptor; P65, RELA proto-oncogene, NF-KB subunit; 
Pi3k, phosphoinositide 3-kinase; Pten, phosphatase and tensin homolog; Reg3ß, 
regenerating islet-derived 3ß; Tnfα, tumor necrosis factor-alpha; Wt1, wilms tumor 1 
bPCR primers used to create plasmid for luciferase assays are named as amplification 
regions of each pair primer sets. -1, -280, -520, -760, -1000, -1100 = 1bp, 280bp, 520bp, 
760bp, 1000bp, 1100 bp upstream of first nuclei acid in the first exon of Insr/Akt1/Akt2;  
cPCR primers used for ChIP assays are named as the amplification regions of each pair 
primer sets. 
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Table 2. Primary and secondary antibodies used in this study 
Antigen Species Working dilution Buffer Source 
Goat-Anti-Rabbit Goat 1:3000 3% milk Bio-Rad Laboratories 
Anti-Goat Donkey 1:1000 3% milk R&D Systems 
Anti-Mouse Goat 1:2000 3% milk BD Pharmingen 
Anti-Rat Goat 1:1000 3% milk R&D Systems 
Donkey-Anti-Mouse Donkey 1:100 3% BSA Life technologies 
ß-Actina Rabbit 1:1000 3% BSA Cell Signaling Technology 
P-Insr Mouse 1:2000 3% BSA Cell Signaling Technology 
Insr Rabbit 1:200 3% milk Santa Cruz Biotechnology 
P-Akt Rabbit 1:2000 3% BSA Cell Signaling Technology 
Akt Rabbit 1:1000 3% milk Cell Signaling Technology 
Socs3 Rabbit 1:1000 3% milk IBL international 
P-P38 Rabbit 1:1000 3% BSA Cell Signaling Technology 
P38 Rabbit 1:1000 3% milk Cell Signaling Technology 
P-Jnk Rabbit 1:1000 3% BSA Cell Signaling Technology 
Jnk Rabbit 1:1000 3% milk Cell Signaling Technology 
Cxcr4 Rabbit 1:5000 3% BSA Novus Biologicals 
His-tag Mouse 1:1000 3% milk Merck Millipore 
Extl3 Mouse 1:100 3% milk Santa Cruz Biotechnology 
Reg3β Rat 1:500 3% BSA R&D Systems 
aAbbreviations: ß-Actin, beta-actin; Akt, protein kinase B; Cxcr4, C-X-C motif 
chemokine receptor 4; Extl3, exostosin like glycosyltransferase 3; Gpx1, glutathione 
peroxidase 1; His-tag, polyhistidine-tag; Insr, insulin receptor; Jnk, the c-Jun NH2-
terminal kinases; P-Akt, phosphor protein kinase B; P-Insr, phosphor insulin receptor; P-
Jnk, phosphor c-Jun NH2-terminal kinases; P-P38, phosphor p38 mitogen-activated 
protein kinases; P38, p38 mitogen-activated protein kinases; Reg3β,	regenerating	islet-derived	3	beta;	Socs3,	suppressor	of	cytokine	signaling	3;	
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Table 3. Plasmid used in this study	
Plasmida Vectorb Inserted Gene Hostc Vector Source 
pPICZαA-Reg3ß pPICZαA Reg3ß P.pastoris GS200
Invitrogen 
Corporation pPICZαA-Cxcl12 pPICZαA Cxcl12 P.pastoris GS200
pPICZαA-Il-6 pPICZαA Il-6 P.pastoris GS200
pcDNA-EGFP pcDNA 3.0 Control HEK293T
Addgene 
pcDNA-Reg3ß-EG
FP pcDNA 3.0 Reg3ß HEK293T 
pmCherry-C3 pmCherry-C3 Control HepG2 
pmCherry-C3-Cxcr
4 pmCherry-C3 Cxcr4 HepG2 
pmCherry-C3-Extl3 pmCherry-C3 Extl3 HepG2 
pAPtag pAPtag-5 Control HEK293T GenHunter 
Corporation pAPtag-Reg3ß pAPtag-5 Reg3ß HEK293T 
pGL3 pGL3 Control HepG2 
Promega 
Corporation 
pGL3 (Insr -250/0) pGL3 Promoter of Insr (-250/0) HepG2 
pGL3 (Insr -500/0) pGL3 Promoter of Insr (-500/0) HepG2 
pGL3 (Insr -1100/0
) pGL3 
Promoter of Insr 
(-1100/0) HepG2 
pGL3 (Akt1 -250/0) pGL3 Promoter of Akt1  (-250/0) HepG2 
pGL3 (Akt1 -500/0) pGL3 Promoter of Akt1  (-500/0) HepG2 
pGL3 (Akt1 -1000/
0) pGL3
Promoter of Akt1 
 (-1000/0) HepG2 
pGL3 (Akt2 -250/0) pGL3 Promoter of Akt2  (-250/0) HepG2 
pGL3 (Akt2 -500/0) pGL3 Promoter of Akt2  (-500/0) HepG2 
pGL3 (Akt2 -1000/
0) pGL3
Promoter of Akt2 
 (-1000/0) HepG2 
pRL-SV40 pRL-SV40 Rl HepG2 
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aAbbreviations: Akt1, AKT serine/threonine kinase 1; Akt2, AKT serine/threonine kinase 
2; AP, alkaline phosphatase; Cxcl12, C-X-C motif chemokine ligand 12; Cxcr4, C-X-C 
motif chemokine receptor 4; EGFP, enhanced green fluorescent protein; Extl3, exostosin 
like glycosyltransferase 3; Il-6, interleukin 6; mCherry, mCherry fluorescent protein; 
Reg3ß, regenerating islet-derived 3ß;  
bpPICZαA,protein expression vector in yeast; pcDNA-EGFP 3.0, pmCherry-C3, pAPtag-
5, pGL3, and pRL-SV40 protein expression vector in mammalian cell line. 
cHepG2, human hepatocyte cell line; HEK293T, Human embryonic kidney 293t cell line. 
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